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Foreword
This aide-memoire records the substance of the presentations and discussions
of a Day of Dialogue—spanning two half-days on 20-21 June 1994 among
representatives of the European donor community and the Population Council
on "Contraceptive Methods For Today and Tomorrow: Developments,
Prospects, and Issues." The discussions covered how contraceptives are
developed, prospects for new technology, areas of controversy surrounding
current and potential methods, and ways to improve the process.
This is the third Day of Dialogue the Population Council has been instrumental
in organizing. The first, on "Population and Feminist Perspectives," was
convened by the Council on 20 November 1992. Its goal was to provide
representatives of the European donor community the opportunity to reflect
on some of the issues between those responsible for shaping population policies
and programs and those groups and individuals whose prime concern is to
promote and protect women's reproductive rights and health. The second
Day of Dialogue, held on 19 November 1993, focused on a broad range of
"Women's Reproductive Health" issues. It was organized for the Advocacy
for Women's Health on behalf of the Commonwealth Medical Association, in
association with the Population Council. All three meetings were held in
London.
The format for these meetings is simple and informal: Population Council
staff and invited experts from other organizations give brief presentations.
This is followed by outspoken and far-ranging discussions over the course of
the day. By design, no consensus is reached or set of recommendations
circulated. Instead, an aide-memoire sent to all participants is the meeting's
record of comments, proposals, and suggestions for follow-up action. The
organizers for the third Dialogue included Sue Perl, the Council's Londonbased consultant, and Valerie Moulay-Omar, a Staff Assistant in New York.
Sandra Waldman served as rapporteur.
The June 20-21 participants saw the Dialogue as a mechanism to elucidate for
the European donors some of the important issues to be discussed at the
International Conference on Population and Development in Cairo in September
1994, and other international meetings within the next year the World Summit
on Social Development in Copenhagen in March 1995 and the Fourth World
Conference on Women in Beijing in September 1995.

ill

Presenters
George F. Brown, Vice President, Programs Division, the Population Council,
presented an overview on contraceptive development and a description of the
contraceptive introduction process.
Rosemarie Thau, Associate Director, Center for Biomedical Research, and
Director, Contraceptive Development, described the research and development
process.
Sandra Waldman, Director of the Council's Office of Public Information,
provided a case study of the introduction and use of NORPLANT® implants
in a developed country the United States.
Beverly Winikoff, a Senior Medical Associate and Program Director,
Reproductive Health, in the Council's Programs Division, contributed closeups
of two research efforts: a study on medical abortifacients in three developing
countries and a collaborative process with women's health advocates on
development of a woman-controlled microbicide.
Marge Berer, editor of the journal, Reproductive Health Matters, gave a
feminist perspective on the contraceptive research process.
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Contraceptive Development I: Why Do We
Need New Methods? What Is the Role of the
Public Sector?
George F. Brown, MD, MPH
Vice President, Programs Division, The Population Council
Dr. Brown provided an historical overview of contraceptive development,
beginning with the introduction of the first intrauterine device (IUD) the
Lippes Loop in the early 1960s. The Loop was hailed as the "magic bullet"
that would enable new family planning programs to offer clients a method that
was highly effective, safe, long-acting, reversible, and inexpensive. This was
the first provider-dependent, long-acting method.
During the 1970s, private pharmaceutical companies decreased efforts in
contraceptive research. The large companies, reacting to such business factors
as the threat of lawsuits, stringent regulatory requirements, decreased patent
protection, increased cost, and limited return on investment, decided to pursue
less controversial and potentially more lucrative research endeavors. In
addition, companies were satisfied with the oral contraceptive market, the first
Pill having been introduced in 1960, and saw little need for new research
beyond tinkering with OC formulations. There was a limited interest in the
developing country market and its priority needs.
Public sector research groups (WHO's Human Reproductive Program, the
Council's International Committee for Contraception Research, and others)
moved to fill the need for additional contraceptive methods. Priority was given
to the needs of developing countries for long-acting methods. The 1970s saw
the introduction of the first generation of copper lUDs, the rapid rise in
sterilization use (now the most widely used method worldwide), and the
beginnings of acceptability research What do user's want? How do they
view the different technology?
In the 1980s, NORPLANT® implants and the second generation of copper
IUD were introduced, along with the first systematic contraceptive introduction
strategies. The HIV/AIDS epidemic highlighted the need for development of
new methods to prevent transmission of sexually transmitted diseases (STDs).
During this decade, the concept of the user's perspective and promotion of
quality of care in family planning programs influenced how services were
conceived, with emphasis on method mix and choice, counseling and
information, and competence of providers. The stronger voice of women's
health advocates enlivened the debate about what contraceptives should be
developed, and to what purpose.

Midway through the 1990s, there is an evident shift from the demographic
rationale for family planning programs to a concern for reproductive health.
Concerns over potential coercive use of contraceptives have led to calls for
woman-controlled methods. Research goals include new methods to prevent
transmission of sexually transmitted diseases (STDs) and development of
medical abortifacients. There also has been the beginning of a systematic
dialogue between biomedical scientists and women's health groups. The most
comprehensive effort to bring together groups involved in family planning
was made at a WHO-sponsored meeting in 1993 in Mexico City.

The need for new contraceptive methods

Additional
contraceptives are
needed for unserved
and underserved
groups.

No one contraceptive method will provide a technological solution to regulating
all fertility. Different types of technology are required for specific unserved or
underserved groups: adolescents (barrier methods, microbicides, abortifacients,
and post-coital methods); younger women (effective birth-spacing methods);
lactating women (methods that have no ill effect on lactation or infant health);
older women (reversible, long-acting methods with fewer side effects); and
men (better barrier methods, long-acting reversible methods). In addition,
attention should be paid to providing quality family planning services for a
range of available methods.
The addition of new contraceptives will expand contraceptive choice but will
not necessarily increase contraceptive prevalence, because the rationale for
family planning programs is changing. Family planning programs should satisfy
individuals' reproductive needs, helping people achieve their reproductive
intentions in a healthful manner, and not focus on furthering demographic
goals.

Place of the public sector
The public sector plays a major role in contraceptive development by focusing
on developing country needs and priorities:
Setting international safety standards;
Considering ethical issues;
Providing low public-sector price for supplies;
Encouraging North-South and South-South collaboration in
development of new methods;
Supporting expansion of the scientific capacity and strength of
developing country institutions;
Assisting countries to expand contraceptive choice and introduce
new methods;
Maintaining collaboration with the private sector;
Conducting acceptability research to understand users' needs; and
Collaborating with women's health groups.

Discussion
Regulatory standards: Discussants wondered how strict PDA standards were,
compared with the past. Although beagle dogs are no longer used for testing
hormonal methods, because reactions are not relevant to human experience,
PDA regulations have become stricter in other ways since the Dalkon Shield
controversy (the Shield did not require PDA approval). Because of stricter
guidelines, the U.S. had fewer thalidomide cases than in Europe. While the
PDA is criticized by those who want faster AIDS research and testing, it was
pointed out that drugs for treatment of lethal diseases have greater urgency
than drugs for prevention of disease. A general discussion ensued on whether
international standards should be set, or whether the PDA ends up setting
standards for all. Each country is different, but the WHO has been helpful in
filling parts of a regulatory review role. The Cairo ICPD document mentions
the setting of uniform standards; efforts are under way by European Community
agencies to set up a European regulatory standard.
Emergency contraception: The widespread use of OCs taken in high dose as a
"morning after" or postcoital pill in Holland is partly responsible for the low
abortion rate in that country. In the U.S., pharmaceutical companies do not
want to market birth control pills for emergency contraception, because the
local medical establishment is opposed and the companies do not want to be
held accountable in case of adverse side effects.

Contraceptive Development II: How Are
New Methods Developed? What Are the
Recent Technologies?
Rosemarie Thau, PhD
Associate Director, Center for Biomedical Research, and
Director, Contraceptive Development, The Population Council
The Population Council's Center for Biomedical Research develops new
methods of contraception and conducts a large basic research program on male
reproductive physiology. The Council has developed the family of Copper T
lUDs, NORPLANT® implants, and a levonorgestrel-releasing IUD. The
development of NORPLANT® II rods and several contraceptive vaginal rings
have reached advanced stages.

The four major areas of current new research at the Council are development
of a variety of methods using the progestin Nestorone (single implant and
vaginal rings); medical abortifacients, such as mifepristone (RU 486); a womancontrolled microbicide for prevention of HIV and chlamydia; and long-acting,
reversible methods for men.
The Council is making a major effort to get mifepristone approved in the United
States by conducting a clinical trial, selecting a manufacturer and a distributor,
and filing the New Drug Application. Having this method approved by the
PDA would make it more acceptable in developing countries and probably for
women all over the world.
A microbicide would prevent transmission of sexually transmitted diseases,
including chlamydia, herpes, and the HIV virus that causes AIDS. Two versions
of the microbicide are desirable: one would permit pregnancy, the other would
be a contraceptive. Mechanism of action studies and screening of compounds
are ongoing and PDA permission to begin a Phase 1 clinical trial is expected.*
The Council hopes to start clinical trials in 1995. The Council also has
conducted a two-week consultation with women's health advocates about
desired characteristics of a microbicide.
Research into methods for men includes a two-implant system and a vaccine.
The implant system involves a peptide implant to suppress sperm production
and an implant containing MENT, a synthetic androgen, to maintain normal
sexual behavior and male sex characteristics. The LHRH vaccine would
suppress sperm production, and be used in conjunction with the MENT implant
described earlier. Advantages of the two methods are that they are highly
effective, long-acting, coitally independent, reversible, and may have other
health benefits. Both are in Phase 1 clinical trials in the U.S.; MENT is being
tested in Chile and Finland.

Driving forces of contraceptive development
Four questions drive contraceptive development: Is a method desirable? Is it
technically feasible? Is it financially feasible? And does it have an acceptable
level of risk?
Desirability: Desirable features of contraceptive methods include:
Ease of use, for the provider and the user;
Meeting the needs of special users, such as teenagers, nursing women,
postmenopausal women, and women who want to space their children;

PDA permission for a Phase I trial was received after this symposium.

Noncontraceptive benefits (oral contraceptives, for example, reduce
the risk of certain cancers while barrier methods help to prevent STDs); To tnake it worth
High effectiveness (sometimes women value fewer side effects more
developing, a new
than efficacy); and
contraceptive has
Low cost (it has to be affordable).

to be desirable,
Technical feasibility: It makes no sense to pursue a lead unless it is technically technically and
possible to accomplish each step required, from the first to the last. The financially feasible,
technical development pathway has five broad avenues of work to be done:
and have an
acceptable level of
Develop the drug: The Council works with drugs generated but not risk.
used by pharmaceutical companies; an example is ST1435, now called
Nestorone progestin, which is being used in a number of products.
Even when the Council works with a drug originated by a
pharmaceutical company, it can still take 20 to 30 years to complete
the development process.

Toxicology studies: Animal toxicity studies have to be carried out
to ensure that the drug is safe for humans. Several years of animal
trials with specific toxicology requirements set by the PDA are carried
out for each stage of clinical trials with humans. For a Phase 1 clinical
trial, for which one might recruit only 10 volunteers, at least two animal
species have to be tested, rat or mouse and rabbit. For larger scale
trials with humans, testing in primates is a prerequisite.
Distribution/manufacturing arrangements: The Council has to
identify a manufacturer to whom it can transfer the technology for
small-scale production developed by Council staff. Then a
manufacturer and distributor must be found who will make a financial
investment and eventually take over final development of the method,
because the Population Council does not synthesize drugs or
manufacture them.
Clinical trials: After proving a method is safe in animals, the Council
has to show that it also is safe and effective in humans. The PDA has
three phases of clinical trials through which new devices must pass.
FDA registration: The Council then must obtain approval for
marketing.

Council protocols and preclinical data are reviewed by the PDA even when a
method is to be tested in another country. The application to the PDA for an
Invesdgational New Drug permit contains the trial's protocol, including an
informed consent document in the volunteer's native language that explains
what is being tested.
Financial feasibility: Donor support is needed for all steps along the
development pathway. The Council can start work only after grant proposals
produce adequate funding. If donors are not convinced that what the institution
is doing is worthwhile, research cannot continue. The Council's contraceptive
research is supported by governments, foundations, and the Council's own
resources.
Acceptable risk: The risks and benefits must be balanced at every step in the
process. If at any time unexpected, dangerous side effects occur, the work is
stopped. There is no specific mathematical equation where one says, the risks
are 10 percent but the benefits are 20 percent, therefore we continue. The
Council works with advisory groups, women's representatives, and physicians
on an ongoing basis.
Even after studies in several animal species and humans have been conducted,
total safety can not be guaranteed. To detect rare adverse events, a postmarketing
surveillance must be initiated in order to follow a much larger number of users.
The Council is now conducting such a surveillance involving 8,000
NORPLANT® users and 8,000 users of lUDs and sterilization in eight countries,
in collaboration with the World Health Organization and Family Health
International.
The time sequence between initiation of contraceptive development and the
approved final product can take between 20 and 30 years. The long time lag
means that methods undergoing clinical trials now will not be available until
after the year 2000. New methods will take even longer.

Discussion
The concept of risk: The discussion focused on different kinds of risks that
should be considered when contraceptives are being developed. When a
contraceptive is very effective, it may produce troublesome side effects; when
the product is not effective enough or not used correctly there is the risk of
pregnancy. The concept of risk should also address the issue of inconvenience,
such as prolonged irregular menstrual bleeding. For 30 years, the priority has
been to create highly effective methods. But women's health advocates have
helped roll back the emphasis on effectiveness. For example, the failure rate
of the cervical cap is much higher than what medical professionals would
have considered desirable. The PDA approved the cap despite its lower

effectiveness because abortion is legal as a backup. The woman choosing a
contraceptive must decide which risk is more important to her side effects or
pregnancy.
Scientists do not really know the full extent of side effects until clinical trials
have been conducted. Methods advance to the next step only if risks and side
effects seem to be acceptable to users. One speaker pointed out that there are
really two different issues the decisionmaking process about whether to
proceed with product development, and defining the risks associated with the
method in question. In the product development stage a side effect might be
identified that would make the product too dangerous for the user, for example,
a contraceptive that causes heart attacks in 10 percent of users. On the other
hand, if a method produced totally irregular bleeding patterns in all women,
its development also would be halted. It might not be a health risk, but it
would be an unacceptable side effect. One participant asked how one weighed
the aggregate risk vs. individual risk of a contraceptive method. The only way
to determine whether that one in 10,000 rare event will occur is through
postmarketing surveillance, which provides a better understanding of the
product but usually does not lead to discontinuation of a method. Even though
the event is relatively rare, it must be brought to the attention of the regulatory
authorities.
Two additional risks should be considered problems related to the delivery
system and whether a method (vaccines, sterilization, lUDs, and NORPLANT®)
has the potential for abusive use. Each country needs to consider whether its
service delivery system can provide a method properly. Acceptability issues
also need to be considered. Many trials do not look at side effects from the
woman's perspective. Researchers should investigate what women want before
they start to develop a method. Developers and providers have to be much
more precise about risks and problems of contraceptives. Women's health
advocates should do more about disseminating this information.
Vaccine contraceptive for women: A lively discussion ensued around issues
related to development of a vaccine contraceptive for women. The Council is
not continuing with development of this method for lack of funds. Biomedical
researchers at the Council think the benefits of the vaccine outweigh its risks
for these reasons: the immunological effect is directed only toward the fertilized
egg; the menstrual cycle is regular; the vaccine is long-acting, reversible, and
private; and it is a non-steroidal method that does not affect the endocrine
system. On the negative side, there could be a six to nine month delay in
fertility return; the vaccine does not protect against HIV; and there is a potential
for abuse by providers or programs. Critics of the vaccine said there is a
qualitative difference between the vaccine concept and others because of fears
that the vaccine somehow will alter the immune system and make people less

capable of withstanding illness, AIDS, and autoimmune diseases. This is
another provider-controlled method, one speaker said, just when we need
another woman-controlled method.
Some participants voiced concerns about the vaccine's safety: what is really
known about effects on the fetus if the pregnancy continued? How is the
immune system affected and what are the long-term effects? The Council
studied these issues in monkeys after the antifertility effects of the vaccine
were reversed by treating the animals with Depo Provera. The monkeys became
pregnant and delivered normal babies. Some offspring were followed through
puberty, and they had normal ovarian and pituitary functions after they became
sexually mature. The Council also studied the effect of the vaccine on the
immune system of monkeys there was no difference between long-term hyperimmunized monkeys and controls. There is no difference in principal between
the auto-immune system and the immune system. Basically more research is
needed to answer some of these questions fully and to demonstrate the method's
safety. If the Council were to resume its research on a vaccine for women and
some of the health concerns were shown to be real, the work would stop.
Several donors wondered whether there was duplication of research effort
between WHO and the Council as each worked on its own vaccine. It was
explained that the vaccines are different and the two groups exchange
information, share data, and attend each other's meetings. The WHO vaccine
has reached clinical trial stage, while work has stopped on the Council's
concept.
Although the vaccine seems to be a most promising lead, some voiced concern
about the method's abuse potential. Opposition from feminist groups is strong,
particularly in India, where some women's health advocates worry that a woman
might never know what kind of injection she is getting or that the vaccine
might be included without a woman's knowledge in a shot apparently intended
for other purposes. Some speakers pointed out that this type of technology
makes people uneasy; it scares them because they think the vaccine tricks the
body into getting rid of something. Other participants countered that, although
this is a real perception, not only among the radical feminist community but
also among a lot of lay people who are frightened by it, it is not valid. The
vaccine does not trick the immune system any more than a progestin tricks the
ovaries into not releasing eggs.
Others expressed the view that untrained people are making claims about the
vaccine. Although the science must be clearly understood before people can
say it is safe, the scientific community is not sharing information with women's
health advocates and has not been open enough. At some point, women's
health advocates have to start trusting the information scientists give them
because the advocates cannot produce the information themselves. There is a
8

strong distrust of science coming into the field; in the end it is not enough for
scientists to say that more research is required to prove the vaccine is safe:
the women's health advocates would not believe the results. One of the biggest
threats posed by the current debate is that opponents might destroy the vaccine
program by preventing research and testing. It is important to know that it
would take at least 20 years for any new vaccine product to be developed,
even technology that could be tested now. This means that a vaccine would
not be available in the near future, if ever. Several speakers wondered if a
vaccine for men would be as strongly opposed as one for women. It is important
for the whole community to be involved in the vaccine debate scientists,
donors, and women's health advocates because the repercussions are so
important.
Microbicide development: Several speakers wondered if work was progressing
as quickly as possible on the Council's microbicide, given the urgency of the
situation. Now that the Council is starting to test a product, additional funding
from donors would help accelerate the work. The Council initiated its own
concept on microbicides, developed the first steps, and then went to donors
for support. This is a high priority program for the Council and funding has
increased significantly during the last few years. Microbicide research currently
takes about 7 to 8 percent of the Council's bioniedical research budget.
Down the road the Council may face a problem in getting the private sector to
be interested in this kind of product for developing country markets. Major
pharmaceutical companies might shy away from a microbicide because of the
issue of liability should the product fail to protect. The Council can proceed
with the development of a product and will not have to work with a commercial
partner until later in the process. The Council does not know if profits would
be large enough from a developing country market to interest a manufacturer.

Contraceptive Introduction
George F. Brown, MD, MPH
Vice President, Programs Division, The Population Council
Prior to 1983, contraceptive introduction was haphazard. With the introduction
of NORPLANT® implants in 1983, the Council began a systematic program
to help interested countries undertake preintroduction and acceptability studies.
The aim of these studies was to help less developed countries design a strategic
plan for training, regulatory filing, logistics, IEC (information, education and
communication), and evaluation. The Council helped develop international
and national training and informational materials. The method also has been

reviewed by WHO and IPPF. Researchers have produced a substantial body
of scientific knowledge. This is the first of a family of implants; others are
sure to come along.
By June 1994, 61 countries had some experience with NORPLANT® implants
and the method has been approved in 39 countries. It is in widespread use in
Indonesia and the United States, but remains in limited use elsewhere. All
told, there are close to 3 million users.

NORPLANT®

The Council has identified a number of problems connected with introduction
implants are not Qf NORPLANT® implants. The first is that it is not well suited to weak health
suited to weak Sy S temS) where training and counseling are inadequate, or where there is a
health systems, difference in service provision between city and rural areas. The Council
^^^^ ^^^^ insisted that the method should be introduced where other methods are
available, to avoid provider bias, but even where other methods are available,
NORPLANT® may still be too expensive. The most difficult issue is the need
for five-year removal, although this is not a deadline that must be met exactly
to the day. Insufficient attention has been paid to training for removal, which
requires follow-up of clients. Indonesia is now experiencing a large number
of 5-year removal cases, and is developing strategies to deal with this demand.
The Council has conducted several research projects on these issues in
Indonesia.
Interval removals also can be a problem if a woman wants removal before the
five years is over and is told she has to wait. The method really is not reversible
if the woman cannot have the implants removed when she wants.
The Council's contraceptive introduction program has now been transformed
into Expanding Contraceptive Choice. It includes a new broader strategy to:
Help programs analyze the full range of clients' contraceptive needs;
Determine a program's capacity to add any new or
underutilized method to better serve clients;
Conduct acceptability research;
Analyze ethical issues;
Evaluate IEC, logistics, training;
Determine overall costs; and
Conduct a dialogue with users and women's groups.
With this new approach, the Council is looking at the capacity of family
planning systems to handle such user-controlled products as the diaphragm
and the condom, because of the need to plan for distribution, information, and
backup abortion services.
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Introducing NORPLANT® in a Developed
Country
Sandra Waldman
Director, Office of Public Information, The Population Council
Nine developed countries have approved marketing of NORPLANT® implants:
Canada, the Czech Republic, Finland, Luxembourg, Romania, the former Soviet
Union, Sweden, the United Kingdom, and the United States. In addition,
clinical trials have been conducted and providers have been trained in Belgium,
Bulgaria, France, and Germany. Wyeth-Ayerst predicts that much of Western
Europe will have NORPLANT® implant approvals in the next two years.
FDA approval for marketing in the U.S. came in December 1990; actual training
and marketing began in February 1991; by mid-1994, more than 900,000 sets
had been sold. NORPLANT® filled a niche in the U.S., which lacked a popular
long-acting method (the IUD never quite recovered from the Dalkon Shield
scandal), and first-year sales were greater than expected. In the U.S. the most
popular method sterilization was employed by 40 percent of couples. The
most popular reversible method was the oral contraceptive at 30.7 percent.
After that, usage dropped to 14.6 percent for the condom, 5.7 for diaphragm,
and 2 percent for the IUD. The American health care system is a mix of public
and private (government clinics, Planned Parenthood and other clinics, and
private physicians). The U.S. distributor trained over 26,000 health care
providers (physicians and nurse practitioners) at 300 training centers. This
training is still going on. Much of the training was accomplished via videos,
with use of a plastic training arm. Seventy of these centers are providing ongoing
training in removals.
However, with all this training, there are still problems: physicians are not
required to be trained before they provide NORPLANT® implants and there is
no requirement for hands-on training. Since the U.S. is a very litigious society,
several lawsuits have already been filed dealing with improper removals. Some
patients also claim they were not given adequate information about known
side effects, although the importance of counseling is emphasized throughout
the training program. Provider bias also poses problems in the U.S. Some
physicians do not want to prescribe NORPLANT® at all because it is much
easier to prescribe a pill; counseling for NORPLANT® takes too much time,
and some think it is a good method only for women who cannot "comply"
with other methods.
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Cost can also be a barrier to NORPLANT® use. Compared with $23 in
developing countries, the method in the U.S. costs $365 for the implants alone,
with physicians charging an additional $150 to $300 for insertions. Women
with private insurance and women who have Medicaid coverage can obtain
NORPLANT® implants, but women without insurance find it too expensive to
use. Two Congressional hearings have been held on access to the method. In
1995 the public sector price will be lowered, a specification included in the
Council's contract with Wyeth-Ayerst.
In addition to all these factors, there is another element that makes the U.S.
situation unique the attempt by some to use NORPLANT® as a social tool,
as a means to cut welfare costs, to prevent child abuse, or to solve teenage
pregnancy problems. Although some state legislatures have proposed payment
of incentives to get women on welfare to use NORPLANT®, not one bill has
actually passed. The few instances of abusive use of NORPLANT® have
been in connection with plea bargaining and reduced jail sentences for convicted
child abusers.

Discussion
Ethical aspects of contraceptive provision: All the participants were adamant
about the need to make sure a contraceptive is not provided abusively. It is not
just implants or vaccines or the IUD that have the potential to be abused
there is a long history of sterilization abuse in many countries. Abuse can be
defined in varying ways pressuring a woman to use one method instead of
another, providing a contraceptive without the woman's knowledge, denying
a woman access to insertion or removal or a choice of methods, making the
cost too expensive, and providing a method without adequate training. Ethical
debates on these questions and others should be encouraged at all levels within
countries. The contraceptive development community, including donors and
researchers, has to engage in the debate early in the process to determine its
own responsibilities. Women's health advocates in some instances have been
helpful in forcing countries to enter the debate, but it is a long educational
process. Rather than trying to set international guidelines, societies have to
decide for themselves how methods will be used. Once a method is approved
in a country, that country has the right to do what it wants with it.
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Second Day
George Brown, M.D.
Dr. Brown highlighted four questions that had emerged as focal points from
the first day's discussions:
How do we ensure the resources to continue contraceptive research
and development?
Does more research have to be done while methods are in early
development?
What should be the focus of responsibility for the actual technology
once it reaches the introduction stage? To make sure it is used
appropriately and ethically? Who maintains quality control?
Who sets the agenda and the priorities? There are various concerned
groups.

Perspectives of a Woman's Health Advocate
on Contraceptive Research, Development
and Introduction
Marge Berer
Editor, Reproductive Health Matters
This talk revolved around four questions:
Are provider-controlled or user-controlled contraceptive methods
better for women?
Are long-acting contraceptive methods undesirable because they
are more open to abuse?
In what ways should the limitations of and potential for abuse during
service delivery influence decisions about contraceptive research and
introduction?
How do the answers to these questions affect priorities for the future?

Definitions of provider- and user-controlled methods
First, Ms. Berer showed the different possible interpretations of provider- and
user-controlled methods. If a contraceptive is provider-controlled, it can mean
simply that a provider must be available and trained to insert and remove the
device or perform the procedure needed in order for the user to obtain or stop
using the method. Or, it can have serious negative meanings: a provider can
insert the device or perform a procedure without the recipient's knowledge or

13

consent. A provider can refuse to provide the method to patients, or can refuse
to remove the method from them. Given these definitions, are injectables
provider controlled? In some places a woman has to go to a provider to obtain
this method, but in Latin America women can buy injections from the pharmacy.
A woman can be pressured to be sterilized or have an abortion against her will
or knowledge. Yet, abortion and sterilization often are refused to women who
request them, requiring permission from a parent, the state, or a partner.
The phrase user-controlled also can have two meanings: the woman decides
whether to use the method and therefore retains control over his/her own fertility
or there is no provider involved and the user can obtain the method directly for
herself/himself. Condoms, diaphragm, and the pill are all considered usercontrolled methods. But women need to be taught by providers how to use the
diaphragm and the pill. A study in South Africa showed women felt empowered
by injectable contraception and felt that it gave them control over pregnancy.
There are two ways of looking at the user/method relationship. In one, the
method itself takes control once it is in place (injectable, implant, IUD,
sterilization); in the other, the user repeatedly has to decide and then take
some action in order to use it (pill, condom, diaphragm, spermicide, natural
methods, withdrawal). When the method takes control, it is easy to start use,
but harder to stop. When the user takes control, it is easy to start, but harder to
continue.

Two ways to prevent abuse
There are two possible ways to prevent abuse of contraceptives. One would
be to ban any or all of the methods that can or have been abused and call a
on the development of similar methods that are being developed
If all methods with moratorium
now or may be developed in the future. The other would be to remove the
the potential for multiple sources of abuse from all levels of national programmes and policies
abuse were and offer an open choice of methods to all contraceptive users.

banned, women
would then have a Women's health advocates act as watchdogs, challenging control of women's
very limited choice fertility by others. Some women's health advocates feel there is only one
of contraception. strategy to call for abandonment of methods that have or can be abused and

a moratorium on injectables, implants, lUDs, or vaccines. But there has been
disagreement on the issue of banning methods for the last 10 years. For
example, in the late 1970s a slogan of the women's health movement was "No
to sterilization abuse" but no one called for a ban on sterilization. The
disagreement began over the call for a ban on Depo Provera. If all of the
above methods and sterilization were eliminated to avoid abuse, women would
have a very limited choice. Methods would not be improved, new systems
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would not be pursued; the only options would be the pill, barrier, or natural
methods. While it is important to have new and improved barrier methods,
there is no evidence from users that they would be satisfied with these alone.

Are long-acting contraceptives desirable?
Long-acting methods such as sterilization, IUD, implants, and Depo Provera
that last more than three months are sometimes equated with provider-controlled
methods. But not all long-acting methods are provider controlled or vice versa.
The vaginal ring, for example, is long-acting yet is user controlled. Some
women prefer a contraceptive that is not 100 percent effective; they are not
sure whether they want a child and prefer to let the contraceptive make the
decision for them. On the other hand, some women are terrified of another
pregnancy and efficacy is all-important to them.
Many women need and want long-acting methods: a woman can get pregnant
during at least 30 years of her life. Even if she needs contraceptives for only
20 of those years, that is 2,000 or more condoms, 240 pill packets, and 80
Depo Provera injections. This is why so many women are opting for
sterilization, NORPLANT®, or IUDs. Many women use pills for 10-15 years
why isn't that considered a long-acting method?

Future priorities
Ms. Berer outlined these priorities:
Pursue promising new methods as scientific advances in
understanding allow, continue trying to improve existing methods,
and try to fill important gaps that exist but accept only those methods
that are at least as safe as existing approved methods. If research is
halted, people will have only those methods in use now. We have
improved the pill and developed no-scalpel vasectomy; but we have
not solved the problem of why condoms break, developed improved
IUD insertion techniques, or devised ways to help women remember
to take the pill. We must also fill in gaps with microbicides, RU 486
(mifepristone), and safe second trimester abortion methods.
Conduct research on the best types of family planning/reproductive
health policy, on service delivery models, and on acceptability of
methods. Sexuality research too often is ignored. Research also is
needed to monitor, reduce, and, if possible, eliminate abuses in family
planning provision while we are seeking to improve the quality of
care.
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Foster equality, dialogue, and cooperation among policymakers,
scientists, service providers, contraceptive users, family planning
associations, women's health advocates, donors, and the media. It is
crucial to encourage and broaden the dialogue on a regional basis,
including Europe. Given the conflicts, disagreements, and
contradictions that prevail, an extensive dialogue is required; to do
otherwise will be destructive.

Discussion
Need to democratize the dialogue: All concerned groups should participate in
the dialogue about contraceptive development. It is the donors' responsibility
to help open up discussion and diversify the actual decision-making process.
Yet contraception alone will not solve all of women's problems. Women also
need other reproductive health services, which should be incorporated into
family planning services. The field needs user research, not market research.
Ways to prevent abuse: One of the most potent ways to prevent abuse is to
give people information so they can make their own choices. Empowerment
comes with knowledge; poor, marginalized people can be given the knowledge
they need to empower themselves. Abuse and power issues occur as part of
service delivery; there ought to be a way to monitor services to prevent abuses.
Some policy issues and responses: When family planning is integrated into
health care programs in developing countries, the emphasis should be on health,
not demographic goals. In the past, many donors were motivated primarily by
demographic goals, but this is changing. Sometimes, donors are confronted
by country indifference to family planning or reproductive health programs;
when that happens, programs appear to be donor-driven, an unfortunate
perception.
Model clinics created by women's health advocates are untapped resources.
In Sao Paulo, Brazil, for example, a women's health clinic serves a small
community and has brought policy people together. Women's health groups
have stimulated renewed interest in the diaphragm in Brazil and India.
The Council employs situation analyses to look systematically at the quality
of family planning and reproductive health services. This is used as a research
tool to help program managers gauge the gap between their desire to provide
quality services and what clients actually receive. Program managers find
situation analyses a reasonably inexpensive and fast way to bring problems to
light. Since resources often are limited, every program should establish its
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own standards. In some countries, there is a backlash related to quality of care
standards, with some program managers concerned that their services will be
rated worse than those of a neighboring country.

New Ways to Take Account of Women's
Perspectives in Technology Development
Beverly Winikoff, MD, MPH
Senior Medical Associate and Program Director, Reproductive Health,
Programs Division, The Population Council

Medical abortion acceptability studies
One new way to take account of women's perspectives is to design studies
differently. The Council has conducted a controlled but not randomized study
in India, China, and Cuba to compare acceptability of medical abortion using
mifepristone (RU 486) with surgical abortion. Women were given a choice
between the two methods. In all places, the medical method was chosen
significantly more frequently by women offered both kinds of abortion. A
questionnaire sought information about the timing and place of abortion, side
effects, services, expectations, and satisfaction. Responses also shed light on
service delivery issues that should be considered. There are variable preferences
with regard to abortion at home/clinic/hospital; rest in bed/ambulatory; presence
of partner/support person. The availability of choice is itself important, an
investment in the experience that makes the experience better.
Any safe and effective method for pregnancy termination will be well accepted
in developing countries, but medical abortion has a special appeal. Considering
that surgical abortion is safe, effective, and available in these countries, women
considered medical abortion to be easy, convenient, quick, private, natural,
and pain free. Another important benefit of medical abortion was that it was
not surgery. The patients also liked the fact that they were conscious (no general
anesthesia), that no hospitalization was required, and that they were not
dependent on others.

Involvement of women's health advocates
Another way to take an account of women's perspectives is to involve women's
health advocates early in the development of a product. A prime example is
the Council's program to develop microbicides. In May 1994, the Council
conducted an eight-day consultation between scientists and women's health
advocates. A primary objective of the consultation was to ensure that the
Population Council's current commitment to microbicide development results
in the availability of a vaginal product that is safe, effective, and meets women's
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needs. In addition, the Council hoped to develop a model for future
contraceptive development that engages women as active partners in all aspects
of the technology development process.

Consultation with
women 's health
advocates will lead
to a microbicide
that better meets
women's needs.

The eight-day consultation initially involved a core group that defined the
objectives and activities during the period, then expanded on the second day
to a broader audience of donor representative, scientists, and Council senior
staff. They reviewed the principal challenges of microbicide development:
scientific issues, the ethics of clinical trials; role of pharmaceutical companies;
and the role of technology in AIDS prevention strategy. Later in the week, the
group met with Washington-based donors, policymakers, activists, researchers,
and congressional leaders. On day seven, the women's health advocates
presented their recommendations to Population Council senior staff and officers
and on the final day, the entire group formulated recommendations and plans
for the next steps, including development of a work plan and proposal for
continued support.
It is not always easy for scientists and women's health advocates to work
together. They do not always speak the same "language," and the consultation
itself may make product development slower. But the process of women's
health advocates and scientists working together, has advantages as well: the
clinical study designs that are developed with women's health advocates are
more sensitive to the realities of the study participants' lives and needs and
are, therefore, more likely to generate realistic data. As a result, the product is
more likely to be accepted and used by the intended beneficiaries. Women's
health advocates can better serve as advocates for a technology once their
understanding has been increased, with study findings disseminated among a
much broader audience. By working together, both groups may benefit from
increased funding opportunities.
The consultation with women's health advocates has had an impact on the
Population Council's microbicide development work. The Council will
endeavor to reexamine and broaden the basic concepts of safety, efficacy, and
acceptability by incorporating women's perceptions in the definition of each
method. In addition, the organization will seek to involve women's health
advocates in the design and implementation of Phase 2 and 3 clinical trials for
vaginal microbicides.
The Council's ongoing microbicide research and development activities include
screening of potential antimicrobial compounds in vitro and formulation and
preclinical evaluation of potentially microbicidal vaginal products. A Phase 1
clinical trial of a new sulphated polymer formulation will be conducted in
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1995. The Council will also conduct acceptability studies of existing
formulations of spermicidal preparations, such as suppository, foam, gel, and
film.

Discussion
Product effectiveness: Some felt that a method to prevent AIDS must be 100
percent effective, unlike contraceptives, where 98 percent is considered good,
particularly if abortion is used as a backup. Others pointed out that a microbicide
will never be 100 percent effective because of the user factor. Fear of method
failure and litigation resulting from it is one reason why major drug companies
avoid doing this kind of research. Speakers wondered if it is better or safer to
have a technology, such as medical abortion, that is 95 percent effective than
to have unsafe abortions. Even where abortion is unsafe, emergency backup
care exists where women can get a dilatation and curettage.
Mifepristone acceptability study: Participants wondered if the mifepristone
acceptability studies reflected cultural differences between India, Cuba, and
China. In China, avoidance of pain was very meaningful because
anesthesiology is very poor in that country. Women in both China and India
felt that privacy was very important. People actually were more the same than
they were different. There will always be unwanted pregnancy and a need for
emergency services.

Suggestions for Future Action
George Brown said the Population Council was encouraged and stimulated by
the discussion and suggested a post-Cairo Dialogue might be worthwhile, with
a broader range of groups included. He posed a series of questions that formed
the basis for the group's proposals for follow-up:
How can we further this debate and broaden the group?
Where can we find the needed resources to advance development of
acceptable contraceptives?
Building on the WHO experience, what more should be done to
engage and include women's health advocates in the decision-making
process?
What future action can this kind of informal dialogue pursue?
Democratize the process: Women's groups criticize how contraceptive
research and development are conducted. Perhaps in the 1990s we have started
to learn something about changing the process. There is a need to democratize
the debate about what methods are developed, how research priorities are set,
and how research is conducted. The parties involved scientists, donors,
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manufacturers, women's health advocates, country policymakers, and service
providers should join the debate to define accountability, responsibility, and
ethical standards.

Regenerate pharmaceutical company interest in
Contraceptive development: Contraceptive research now is
undertaken largely by the public sector with support from a few governments
and private foundations. Public sector organizations such as the Council are
very dependent ultimately on collaboration with the pharmaceutical industry
for manufacture and marketing. This collaboration needs to be strengthened
to include earlier contact with companies to gain access to products on their
shelves. Companies should be educated about the contraceptive demand in
developing countries and the special needs of the women and men there. In
the case of a product such as microbicide, industry should be shown there will
be a big enough profit margin in developed countries to enable them to provide
a public sector price in developing countries. Collectively, donors and others
must provide the leverage to convince the private sector to get back into
contraceptive development, to create appropriate technology for developing
countries. As a follow-up to this event, the participants suggested holding
another Day of Dialogue to open a four-way partnership WHO and the
Council, elements of industry, donors, and women's health advocates to
encourage product research and development.

Establish a fund for contraceptive procurement:
Determine whether it is possible and desirable to establish a special
European fund to assist developing countries in contraceptive procurement.

Conduct social science research to improve service
delivery: Provision of contraceptive technology should not be divorced
from the service context into which it will be delivered. Improved approaches
and research are needed to focus on service delivery, including the question of
accountability and the essential package of reproductive health.
Improve diagnostic tools for STDs: Efforts should be broadened
to develop reasonable and effective diagnostic equipment for STDs. Despite
offers of rewards to developers of such products and attempts to foster
collaboration with industry, efforts so far have produced no interested
developers. Such diagnostic methods are essential in efforts to integrate relevant
reproductive health services into family planning programs.

Expand the dialogue with women's health advocates:
We need more creative ways to enhance the dialogue with women's health
advocates and more acceptability research to reveal what women and men
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want. While women's health advocates have made some progress at the national
level in some countries, they are not accepted as full partners in an ongoing
discussion about health services. Donors can promote constructive discussions
within countries among policymakers, service providers, and women's health
advocates. IPPF and its member associations can be good partners in this
endeavor.
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